Chemotherapy Clinical Trial
Official title:
A Clinical Study on the Safety and Efficacy of Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)
Innate immune cells are an important part of the body's innate immune system, the first line of defense against infection and cancer. Tumor killer cells (TKC) are mixed cultures of two kinds of innate immune cells, namely natural killer cells (NK cells) and gamma delta T cells (γδT cells), which are co-activated and co-cultured ex-vivo in a certain proportion by the unique TKC technology. Adoptive TKC transfer is expected to exert a strong anti-tumor effect through synergistic action between NK cells and γδT cells. In this study, the safety, tolerance, and preliminary efficacy of adoptive TKC transfer combined with chemotherapy will be examined in patients with advanced NSCLC.
Primary Objective: ● To describe the safety profile and toxicity tolerance of combining adoptive TKC transfer with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Secondary Objectives: ● To evaluate the preliminary efficacy of combining adoptive TKC transfer with chemotherapy in the treatment of advanced NSCLC. Design: - This is a single-centre, open label, non-randomised, no control clinical trial. - NK cells and γδT cells are isolated from the patients' peripheral blood mononuclear cells (PBMCs) obtained before chemotherapy and then co-cultured with TKC technology ex-vivo. The mixed cultures will be used in multiple infusions under administration. The first infusion will be conducted in 7-10 days after chemotherapy and is assessed by the investigators. - Clinical responses will be evaluated closely in about 30 days and last up to 2 years after treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03652727 -
FX vs. ECG Guidance for PICC Insertion
|
N/A | |
Not yet recruiting |
NCT05856656 -
Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Recruiting |
NCT00797238 -
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC
|
N/A | |
Not yet recruiting |
NCT05927857 -
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
|
Phase 1/Phase 2 | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT04466332 -
Comparison of Two ECG Guided PICC Insertion Techniques
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03701607 -
Effect of Chemotherapy on PD-L1 in NSCLC
|
||
Recruiting |
NCT04024241 -
Medium Dose of Cytarabine and Mitoxantrone
|
||
Recruiting |
NCT06208436 -
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
|
||
Recruiting |
NCT05306301 -
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
|
Phase 2 | |
Active, not recruiting |
NCT02304640 -
Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
|
||
Completed |
NCT02298972 -
Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer
|
N/A | |
Terminated |
NCT01249001 -
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
|
Phase 2 | |
Recruiting |
NCT03089892 -
A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy
|
N/A | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Recruiting |
NCT04472403 -
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
|
||
Terminated |
NCT02982694 -
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
|
Phase 2 |